Click Here For COVID-19 (Coronavirus) Studies

RecruitMe Clinical Trial

An Open-label, Multi-drug, Multi-center Phase II Combination Study of AZD4635 in Patients with Prostate Cancer
Study of AZD4635 in Patients with Prostate Cancer
Sponsor:AstraZeneca
Enrolling:Male Patients Only
Minimum Age:18 years old
IRB Number:AAAS6539
U.S. Government ID:NCT04089553
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information:

The purpose of this study is to find a more effective treatment as well as to gain a better understanding of prostate cancer. This study includes investigational study drugs which are specific for your prostate cancer (module). Treatment in each module will include an investigational medication called AZD4635 as well as another module-specific study drug(s). The combination of AZD4635 and the module-specific drug(s) is expected to stimulate your immune system to help fight your cancer.

Do You Qualify?
Are you a male of at least 18 years of age?YesNo
Do you have prostate cancer?YesNo
Have you taken standard of care therapies?YesNo
Are you able to perform everyday work independently?YesNo
Submit
Cancel
You may be eligible for this study

Place Holder




Who Can I Contact?
For more information, please contact:
Research Nurse Navigator
Email: cancerclinicaltrials@cumc.columbia.edu
Phone: 212-342-5162